Published in final edited form as:

Bioorg Med Chem Lett. 2015 November 1; 25(21): 4854–4857. doi:10.1016/j.bmcl.2015.06.044.

Exploration of the Structure-Activity Relationship of 1,2,4-Oxadiazole Antibiotics

Derong Ding, Marc A. Boudreau, Erika Leemans, Edward Spink, Takao Yamaguchi, Sebastian A. Testero, Peter I. O'Daniel, Elena Lastochkin, Mayland Chang*, and Shahriar Mobashery*

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA

Abstract

We have recently disclosed the discovery of the class of 1,2,4-oxadiazole antibiotics, which emerged from *in silico* docking and scoring efforts. This class of antibacterials exhibits Gram-positive activity, particularly against *Staphylococcus aureus*. We define the structure-activity relationship (SAR) of this class of antibiotics with the synthesis and evaluation of a series of 59 derivatives with variations in the C ring or C and D rings. A total of 17 compounds showed activity against *S. aureus*. Four derivatives were evaluated against a panel of 16 Gram-positive strains, inclusive of several methicillin-resistant *S. aureus* strains. These compounds are broadly active against Gram-positive bacteria.

Graphical Abstract

Keywords

1,2,4-oxadiazoles; structure-activity relationship; Antibiotics

The Gram-positive bacterium *Staphylococcus aureus* is commensal to humans and exists on the skin and mucosa of 30% of the population.^{1,2} It is a principal cause of hospital infections, the most frequent and serious of which are bacteremia and endocarditis in hospitalized patients.^{3–6} This organism has become resistant to many different classes of antibiotics.^{7,8} Of special concern are the strains designated as methicillin-resistant *S. aureus* (MRSA), which are broadly resistant to most β -lactam antibiotics, agents of historic choice

*Corresponding author: Shahriar Mobashery, Tel: 1-574-631-2933, Fax: 1-574-631-6652, mobashery@nd.edu.

Supplementary data Supplementary data (synthetic information and the NMR spectra of representative compounds) associated with this article can be found, in the online version.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

for treatment of infections by *S. aureus*. There has been recent activity in discovery of novel antibiotics for treatment of *S. aureus* infections,⁹ but emergence of antibiotic-resistant variants is inevitable, necessitating search for novel classes of antibiotics effective against these organisms.

We recently reported the discovery of the 1,2,4-oxadiazole class of antibiotics, which emerged from *in silico* docking and scoring, followed by screening against the ESKAPE panel of bacteria.^{10,11} This class of antibiotics targets the cell wall for inhibition, it exhibits good *in vitro* and *in vivo* activity and it is orally bioavailable.^{10,11}

The 1,2,4-oxadiazoles are generally comprised of four rings, designated as A, B, C and D, as indicated by the representative compound **1a** (Fig. 1). A hydrogen-bond donor in the A ring is necessary for antibacterial activity. The phenol, aniline and some heterocycles with hydrogen-bonding capability, such as pyrazoles, are tolerated. However, some substituents at this site such as sulfonamides, amides and carboxylic acids reduce the antibacterial activity or are inactive.¹¹ Hydrogen-bond acceptors on the A ring are not favored. As indicated, pyrazoles with halogen substituents are all active, as is the indole at the A ring. Other variants with heteroaromatic systems such as pyridines, triazoles and pyrroles generally lose activity, as do the ones with aliphatic heterocycles.¹¹

We outline here our preparation and evaluation of a series of 59 additional oxadiazole analogs. In general, the derivatives have attempted to explore the effect of structural diversity on the antibacterial activity on the right-hand side of the molecule in the perspective depicted in Fig. 1. The diverse analogs were selected for variation in rings C or in rings C and D, inclusive of fused-ring variants (Fig. 2). These studies further define the structure-activity relationship (SAR) for this class of antibacterials.

The general synthesis of this library followed the methodology reported earlier, as depicted in Scheme 1.⁵ Nitrile intermediates with the C and D rings fused were commercially available (examples **26** and **33**). The nitrile intermediates **2–50** were key to the formation of the 1,2,4-oxadiazole derivatives. The biphenyl ether fragment can be formed through Ullmann reaction or aromatic substitution. The former takes place between aryl iodides and phenol in the presence of CuI, Cs₂CO₃ and *N,N*-dimethylglycine. HCl at 90 °C. Nucleophilic aromatic substitution between the aryl fluorides and phenol was accomplished using K₂CO₃ as base. With the nitriles **2–50** in hand, the amidoximes were easily generated from the reaction between the nitrile and hydroxylamine in ethanol. Under the standard conditions, the acyl chloride was allowed to react with amidoxime in the presence of pyridine under reflux to afford the key 1, 2, 4-oxadiazole intermediates. Removal of the protective groups furnished the final compounds. For example, the Boc group was removed by exposure to acid and deprotection of the benzyl was performed in the presence of BBr₃.

These compounds were screened for antibacterial activity by determination of minimal-inhibitory concentrations (MICs) against the ESKAPE panel of bacteria, including *S. aureus* ATCC29213. Active compounds were designated as those with MIC values of $\leq 8 \mu\text{g/mL}$, which encompassed 17 of the synthetic compounds. The MIC data and the corresponding structures are listed in Fig. 2. All the active derivatives (**51a–67a**) have the phenol moiety as

the A ring. Compounds **51a** and **52a** displayed identical antibacterial potency with an MIC value of 2 µg/mL, which indicated both the electron-withdrawing group chlorine or the electron-donating hydroxyl were well tolerated. Other substituents such as iodine, fluorine and the nitro group at the R¹ and R² positions showed the same trend. Interestingly, compound **68a** with the NH₂ group at R² did not have any antibacterial activity. A small difference in antibacterial activity was observed between **55a** and **58a** with the switching of the NO₂ group between the R¹ and R² positions (MIC = 4 µg/mL *versus* MIC = 8 µg/mL). On the contrary, when the position of the azide was changed between R¹ and R², one compound (**53a**) demonstrated activity and the other (**69a**) was inactive. Intriguingly, chlorine as a substituent exhibited the opposite trend between the R¹ and R² positions (**52a** and **70a**). Replacement of the bridging oxygen with sulfur, compounds **61a**, **62a**, **63a** and **65a**, did not alter the activity. Also, substitution of oxygen by the NH group (**64a**) retained activity, although there was a two-fold effect on the MIC value. It is of note that, compound **86a** with the oxygen substituted by CH₂ resulted in inactivity, so did replacement of oxygen with NH (**85a**). The CO, SO and SO₂ groups at the same location behaved the same way, resulting in the loss of activity (**87a**, **89a** and **90a**). The more polar piperidine derivative **67a** was active (MIC = 8 µg/mL).

Other attempts to introduce piperidine (**93a**) or piperazine (**102a**) failed to produce active compounds. Compounds **74a–76a** with pyridine rings were devoid of activity. Most of the compounds with the C and D rings fused were inactive, except **59a** and **60a**, which exhibited activity with an MIC of 8 µg/mL. Isomeric compounds **59a** and **60a** showed the same activity, indicating that the different positions for the indole nitrogen did not affect the antibacterial activity. The substitution of the indole nitrogen by O, S or NBn resulted in inactive compounds (**71a**, **72a** and **73a**). Our previous work indicated that several derivatives with 4-chloro pyrazole or indole as the A ring and the biphenyl ether for the C and D rings have potent antibacterial activity⁵ However, the variants prepared in the present study in which the C and D rings were fused did not result in active compounds.

This SAR effort based on a library of 59 compounds established a number of important observations on the oxadiazole antibiotics. These are: (i) structural variations on the C ring can support antibacterial activity; (ii) substitutions of oxygen for sulfur at the bridging moiety between rings C and D can generally be tolerated, but other moieties at the same site are detrimental; (iii) fusion of rings C and D with the phenol as the A ring retains activity; (iv) variations on the C ring abolish activity, if the A ring is either pyrazole or indole.

Antibiotics **51a–53a** and **63a** were evaluated with a larger panel of 16 Gram-positive bacteria, including antibiotic-resistant strains (Table 1). The properties of these strains are given in the footnotes to the table. These compounds in general exhibit broad activity against many of these leading Gram-positive bacterial pathogens.

We have described in this report the design, synthesis and the antibacterial activity against Gram-positive bacteria of a series of 1,2,4-oxadiazole analogs with modifications on the C ring or on the fused C and D rings. This study defines the structural properties of this novel class of antibacterials, which emerged from an *in silico* search and screening.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was financially supported by grant AI090818 from the National Institutes of Health (to M.C. and S.M.).

References

1. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, McDougal LK, Chaitram J, Jensen B, Fridkin SK, Killgore G, Tenover FC. J Infect Dis. 2006; 193:172. [PubMed: 16362880]
2. Ryu S, Song PI, Seo CH, Cheong H, Park Y. Int J Mol Sci. 2014; 15:8753. [PubMed: 24840573]
3. Watkins RR, David MZ, Salata RA. J Med Microbiol. 2012; 61:1179. [PubMed: 22745137]
4. García-Álvarez L, Holden MTG, Lindsay H, Webb CR, Brown DFJ, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RLR, Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA. Lancet Infect Dis. 2011; 11:595. [PubMed: 21641281]
5. Ippolito G, Leone S, Lauria FN, Nicastrì E, Wenzel RP. Int J Infect Dis. 2010; 14S4:S7. [PubMed: 20851011]
6. Gould IM, Reilly J, Bunyan D, Walker A. Clin Microbiol Infect. 2010; 16:1721. [PubMed: 20825434]
7. Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, Hoban DJ. Canadian Antimicrobial Resistance Alliance. Antimicrob Agents Chemother. 2010; 54:4684. [PubMed: 20805395]
8. US Department of Health and Human Services Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>
9. Tran MCN, Naumovski S, Goldstein EJC. Am J Clin Dermatol. 2015; 1007/S40257-015-0125-9
10. O'Daniel PI, Peng Z, Pi H, Testero SA, Ding D, Spink E, Leemans E, Boudreau MA, Yamaguchi T, Schroeder VA, Wolter WR, Llarrull LI, Song W, Lastochkin E, Kumarasiri M, Antunes NT, Espahbodi M, Lichtenwalter K, Suckow MA, Vakulenko S, Mobashery S, Chang M. J Am Chem Soc. 2014; 136:3664. [PubMed: 24517363]
11. Spink E, Ding D, Peng Z, Boudreau MA, Leemans E, Lastochkin E, Song W, Lichtenwalter K, O'Daniel PI, Testero SA, Pi H, Schroeder VA, Wolter WR, Antunes NT, Suckow MA, Vakulenko S, Chang M, Mobashery S. J Med Chem. 2015; 58:1380. [PubMed: 25590813]
12. Wang H, Lee M, Peng Z, Blazquez B, Lastochkin E, Kumarasiri M, Bouley R, Chang M, Mobashery S. J Med Chem. 2015; 1021/jm501831g

Figure 1.
The structure of compound 1a

Figure 2. Results of *in vitro* antibacterial activity against *S. aureus* ATCC29213 of the new 1,2,4-oxadiazole derivatives. The functional groups in ring C were changed to produce all the synthetic compounds in this series and Y was limited to the three indicated entities. MIC values were measured in µg/mL and active compounds have an MIC ≤ 8 µg/mL.

Scheme 1.

General synthetic route to the 1,2,4-oxadiazoles, and the intermediates (2–50) used for variations within the C ring or the C and D rings fused. Aromatic substitution condition: K_2CO_3 , DMF, 60–100 °C; Ullmann reaction condition: CuI, CS_2CO_3 , *N,N*-dimethylglycine. HCl, 1,4-dioxane 90 °C.

Table 1

Minimal-Inhibitory Concentrations (MICs) of Oxadiazoles^a

microorganism	MIC (μg/mL)					
	51a	52a	53a	63a	vancomycin ^j	
<i>S. aureus</i> ATCC 29213 ^b	2	2	2	2	2	1
<i>S. aureus</i> ATCC 27660 ^c	16	8	4	2	2	1
<i>S. aureus</i> NRS100 (COL) ^c	16	8	4	2	2	2
<i>S. aureus</i> NRS119 ^d	8	4	4	2	2	2
<i>S. aureus</i> NRS120 ^d	8	4	4	2	2	2
<i>S. aureus</i> VRS1 ^e	8	2	2	2	2	512
<i>S. aureus</i> VRS2 ^f	8	2	2	2	2	64
<i>S. epidermis</i> ATCC 35547	16	4	2	2	2	16
<i>S. hemolyticus</i> ATCC 29970	8	4	2	2	2	2
<i>B. cereus</i> ATCC 13061	8	4	4	8	1	1
<i>B. licheniformis</i> ATCC 12759	16	2	4	1	0.5	0.5
<i>E. faecalis</i> ATCC 29212 ^b	8	4	2	2	2	2
<i>E. faecalis</i> 201 (Van S) ^g	8	4	4	2	1	1
<i>E. faecalis</i> 99 (Van R) ^h	16	4	4	2	128	128
<i>E. faecium</i> 119-39A (Van S) ^g	8	4	4	2	0.5	0.5
<i>E. faecium</i> 106 (Van R) ^h	8	4	4	2	256	256
<i>E. faecium</i> C68 ⁱ	8	4	4	2	64 ^k	64 ^k

^a Whereas the compounds were screened against the ESKAPE panel of bacteria, they exhibited antibacterial activity only against Gram-positive bacteria.

^b A quality-control strain susceptible to methicillin to monitor accuracy of MIC testing.

^c *mecA* positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid.

^d *mecA* positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid.

^e Vancomycin-resistant MRSA (*vana*) clinical isolate from Michigan.

^f Vancomycin-resistant MRSA (*vana*) clinical isolate from Pennsylvania.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

 g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. i Clinical strain isolated in Cleveland hospitals; most prevalent vancomycin-resistant *E. faecium* strain from Cleveland hospitals. j Data from reference 10; reproduced here for the sake of comparison. k Data from reference 12; reproduced here for the sake of comparison.